• Sat. Oct 23rd, 2021

Covid, the study on non-steroidal anti-inflammatory drugs

Byeditorial

May 8, 2021

Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, “do not increase mortality” from Covid-19 and “neither do the severity of the disease”. It is the fixed point set by the largest observational study conducted so far on patients hospitalized with the disease caused by the coronavirus Sars-CoV-2 and published in ‘The Lancet Rheumatology’. Based on the results of the work, which examined over 72,000 people, the authors therefore recommend that doctors continue to prescribe and manage non-steroidal anti-inflammatory drugs in the same way as before the onset of the pandemic. The analysis was carried out in the UK. These common drugs used to treat acute pain and for rheumatological diseases, such as rheumatoid arthritis and osteoarthritis, ended up at the center of the debate at the beginning of the pandemic: the question arose whether their use could increase the severity of Covid-19 and the request for urgent investigations on this front has been raised. The data collected by the researchers in the ‘Isaric Ccp-Uk’ study show that about one third of patients (30.4%; 1,279 out of 4,211) who had taken these medicines before hospitalization for Covid died. A similar rate (31.3%. 21,256 out of 67,968) to that recorded in patients who had not taken NSAIDs. Mortality did not increase in patients with rheumatology either. “We now have clear evidence that NSAIDs are safe to use in patients with Covid, which should reassure both doctors and patients that they can continue to be used in Covid. way before the pandemic “concludes Ewen Harrison, University of Edinburgh, lead author of the study, stressing the importance of this result given that” many people rely “on these molecules” to carry out their daily activities. When the pandemic is started more than a year ago, we needed to be sure that these common drugs would not lead to worse outcomes “in Covid sufferers. The study collected data on prescribed drugs, which patients were taking or had taken within 14 days prior to hospital admission. , as well as demographic information and medical history. Patients involved in the work were admitted to 255 healthcare facilities in England, Scotland and Wales between January and August 2020. 5.8% (4,211) had taken NSAIDs prior to admission. The study did not determine whether patients continued to take these drugs while they were in the hospital, so the authors cannot make recommendations in this regard.